Search Results - "Loosveld, Eline"

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers by van der Lee, Miranda M C, Groothuis, Patrick G, Ubink, Ruud, van der Vleuten, Monique A J, van Achterberg, Tanja A, Loosveld, Eline M, Damming, Désirée, Jacobs, Daniëlle C H, Rouwette, Myrthe, Egging, David F, van den Dobbelsteen, Diels, Beusker, Patrick H, Goedings, Peter, Verheijden, Gijs F M, Lemmens, Jacques M, Timmers, Marco, Dokter, Wim H A

“…SYD985 is a HER2-targeting antibody-drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin payload. To evaluate the…”
Get full text

Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform by Dokter, Wim, Ubink, Ruud, van der Lee, Miranda, van der Vleuten, Monique, van Achterberg, Tanja, Jacobs, Danielle, Loosveld, Eline, van den Dobbelsteen, Diels, Egging, David, Mattaar, Ellen, Groothuis, Patrick, Beusker, Patrick, Coumans, Ruud, Elgersma, Ronald, Menge, Wiro, Joosten, John, Spijker, Henri, Huijbregts, Tijl, de Groot, Vincent, Eppink, Michel, de Roo, Guy, Verheijden, Gijs, Timmers, Marco

“…A linker-drug platform was built on the basis of a cleavable linker-duocarmycin payload for the development of new-generation antibody-drug conjugates (ADC). A…”
Get full text

Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice by Ubink, Ruud, Dirksen, Eef H C, Rouwette, Myrthe, Bos, Ebo S, Janssen, Ingrid, Egging, David F, Loosveld, Eline M, van Achterberg, Tanja A, Berentsen, Kim, van der Lee, Miranda M C, Bichat, Francis, Raguin, Olivier, van der Vleuten, Monique A J, Groothuis, Patrick G, Dokter, Wim H A

“…Carboxylesterase 1c (CES1c) is responsible for linker-drug instability and poor pharmacokinetics (PK) of several antibody-drug conjugates (ADC) in mice, but…”
Get full text

Abstract 4043: SYD985 synergy with PARP inhibitors (PARPi) in human tumor cell lines and patient-derived xenografts (PDXs) by Dokter, Wim H., Dijcks, Fred A., Groothuis, Patrick G., Mattaar, Ellen, Loosveld, Eline, Jacobs, Daniëlle, van der Vleuten, Monique, Schellens, Jan H., van der Lee, Miranda

“…Abstract SYD985 is a HER2-targeting antibody-drug conjugate comprised of a cleavable linker and the prodrug seco-DUBA which, upon release, spontaneously…”
Get full text

Abstract 5360: The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers by Dokter, Willem, van der Lee, Miranda, Groothuis, Patrick, Ubink, Ruud, van der Vleuten, Monique, van Achterberg, Tanja, Loosveld, Eline, Damming, Desirée, Rouwette, Myrthe, Egging, David, van den Dobbelsteen, Diels, Beusker, Patrick, goedings, peter, Verheijden, Gijs, Lemmens, Jacques, Timmers, Marco

“…Abstract SYD985 is a HER2-targeting ADC based on trastuzumab and vc-seco-DUBA, Synthon's proprietary cleavable linker-duocarmycin payload. Vc-seco-DUBA was…”
Get full text

Abstract 2652: In vitro and in vivo antitumor activity of SYD985, a novel HER2-targeting ADC: a comparison with T-DM1 by Dokter, Willem H.A., Lee, Miranda van der, Groothuis, Patrick, Achterberg, Tanja van, Loosveld, Eline, Jacobs, Daniëlle, Vleuten, Monique van der, Beusker, Patrick H., Hooftman, Leon, Goedings, Peter, Verheijden, Gijs, Timmers, Marco

“…Abstract SYD985 is a HER2-targeting ADC based on trastuzumab and Synthon's proprietary cleavable linker-duocarmycin payload. The preclinical profile, including…”
Get full text